Breast implants are not lifetime devices. The longer a woman has implants, the more likely it is that she will need to have surgery to remove or replace them. The most frequent complications and adverse outcomes experienced by breast implant patients include capsular contracture, reoperation, and implant removal (with or without replacement). Other common complications include implant rupture with deflation, wrinkling, asymmetry, scarring, pain, and infection. In addition, women with breast implants may have a very low but increased likelihood of being diagnosed with anaplastic large cell lymphoma (ALCL).
When you're in the thick of the recovery, it seems like you're going to look and feel that way forever. But honestly, I moved through it so quickly. Days two and three were the toughest, but witnessing my body heal like that was pretty incredible. Each day, I looked considerably different from the day before, which is strange — you really can't get too attached to any one image in the mirror because you know it's still evolving.
When I moved to New York City after graduation, and began establishing myself and building a career, I suddenly felt the time was right to revisit the procedure. I met with Adam Kolker, a well-known plastic surgeon here in New York City, and immediately felt safe and heard. I respected his delicate, conservative approach and appreciated how he spent real time listening to my concerns and making sure I felt comfortable.
Case 31: This patient had some typical concerns of feeling washed out from the front with flattening and spreading of her tip. She was very happy with the narrowing and definition achieved for her bridge and tip along with nostril reduction. In addition, chin augmentation increased chin projection to improve the balance of her lower face and jawline.
The current lifetime risk of BIA-ALCL in the U.S. is unknown, but estimates have ranged between estimated to be between 1 in 70,000 to 1 in 500,000 women with breast implants according to MD Anderson. Certain geographic locations have demonstrated variable risks. For instance, a December 2016 update from the Therapeutic Goods Administration of Australia and New Zealand reported a risk of 1:1,000 to 1:10,000 for textured implants.". To date (2017), there has not been a case of BIAL reported where the patient had only implantation of smooth shell breast implants or a textured tissue expander that was exchanged for a smooth implant. The paucity of cases reported in Asian populations has raised the possibility that there may be a range of genetic susceptibility to the phenomena, or alternatively merely reflect differences in how cases are identified and reported.